Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients

Mary L. Disis, Vivian Goodell, Kathy Schiffman, Keith L. Knutson

Research output: Contribution to journalArticle

97 Scopus citations


HER-2/neu is a tumor antigen in patients with breast and ovarian cancer. Multiple varieties of vaccine strategies are being developed to immunize patients against HER-2/neu. Studies in animal models have demonstrated both T cell and antibody immunity are needed to mediate an antitumor response. Thirty-five patients, immunized with HER-2/neu peptide based vaccines, were evaluated for the generation of HER-2/neu-specific antibody immunity. Sixty percent of patients developed HER-2/neu IgG specific antibody responses to at least one peptide included in their vaccine. Twenty-nine percent of patients developed IgG immunity to the native HER-2/neu protein after peptide immunization. Humoral intramolecular epitope-spreading within the HER-2/neu protein occurred in 49% of immunized patients. Intermolecular epitope-spreading to p53 was evident in 20% of vaccinated patients. Of those patients who developed new immunity to p53, 71% had demonstrated antibody epitope-spreading within HER-2/neu.

Original languageEnglish (US)
Pages (from-to)571-578
Number of pages8
JournalJournal of Clinical Immunology
Issue number5
StatePublished - Sep 1 2004



  • Antibody
  • HER-2/neu
  • breast
  • epitope-spreading
  • ovarian
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this